Therapeutic Lifestyle Changes Improve HDL Function by Inhibiting Myeloperoxidase-Mediated Oxidation in Patients With Metabolic Syndrome
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: OBJECTIVE: Phagocyte-derived myeloperoxidase (MPO) and proinflammatory HDL are associated with metabolic syndrome (MetS) and increased cardiovascular disease risk. Therapeutic lifestyle changes (TLCs), such as a Mediterranean diet and exercise, decrease this risk. However, the link among TLCs, HDL, and MPO-mediated oxidative stress remains unclear. RESEARCH DESIGN AND METHODS: In this study, we characterized changes in cholesterol efflux capacity (CEC), a metric of HDL function; MPO-mediated oxidation; and the HDL proteomic profile in 25 patients with MetS who underwent 12 weeks of TLCs. RESULTS: After 12 weeks, before significant changes to HDL levels, most MetS components improved as a result of the TLCs. CEC was significantly increased, and HDL MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were decreased with TLCs. The changes in CEC were inversely related to the unit changes in 3-chlorotyrosine after we controlled for changes in the other MetS components. TLCs did not remodel the HDL proteome. CONCLUSIONS: In summary, TLCs improved HDL function by inhibiting MPO-mediated oxidative stress even before appreciable changes in HDL levels.
Source: Diabetes Care
DOI: 10.2337/dc18-0049
Language: English
Subfield: Clinical Biochemistry
Domain: Life Sciences
Open Access status: green
Awards: Myeloperoxidase, Chronic Kidney Disease and Atherosclerosis, G3057754795, University of Michigan O'Brien Kidney Translational Core Center, Michigan Center for Diabetes Translational Research, Michigan Diabetes Research Center (MDRC), Michigan Nutrition Obesity Research Center, MPO, HDL Dysfunction and Cardiovascular Disease
OpenAlex ID: W2892240923
